The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
Open accessAbstract
Background and Aims: Normal alkaline phosphatase (ALP) levels in ursodeoxycholic acid (UDCA)-treated patients with primary biliary cholangitis (PBC) are associated with better long-term outcome. However, second-line therapies are currently recommended only when ALP levels remain above 1.5 times the upper limit of normal (×ULN) after 12-month UDCA. We assessed whether, in patients considered good responders to UDCA, normal ALP levels were associated with significant survival gains. Approach and Results: We performed a retrospective cohort study of 1047 patients with PBC who attained an adequate response to UDCA according to Paris-2 criteria. Time to liver-related complications, liver transplantation, or death was assessed using adjusted restricted mean survival time (RMST) analysis. The overall incidence rate of events was 17.0 (95% CI: 13.7–21.1) per 1000 out of 4763.2 patient-years. On the whole population, normal serum ALP values (but not normal gamma-glutamyl transpeptidase (GGT), alanine aminotransferase (ALT), or aspartate aminotransferase (AST); or total bilirubin < 0.6 ×ULN) were associated with a significant absolute complication-free survival gain at 10 years (mean 7.6 months, 95% CI: 2.7 - 12.6 mo.; p = 0.003). In subgroup analysis, this association was significant in patients with a liver stiffness measurement ≥ 10 kPa and/or age ≤ 62 years, with a 10-year absolute complication-free survival gain of 52.8 months (95% CI: 45.7–59.9, p < 0.001) when these 2 conditions were met. Conclusions: PBC patients with an adequate response to UDCA and persistent ALP elevation between 1.1 and 1.5 ×ULN, particularly those with advanced fibrosis and/or who are sufficiently young, remain at risk of poor outcome. Further therapeutic efforts should be considered for these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“First there is clinical survival data to suggest that normalisation is associated with the lowest risk to long-term survival.34”
From Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid (2026) · cites this paper as [34]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This response was especially true in younger patients and patients with advanced fibrosis.113”
From Primary biliary cholangitis. (2024) · cites this paper as [113]
The cited source says what the claim attributes to it.
In the citing paper
“While normalisation of alkaline phosphatase levels has been associated with improved long-term outcomes in patients receiving ursodeoxycholic acid alone, 111,113 it remains unclear whether this association holds true for combination therapy, warranting further investigation.”
From Primary biliary cholangitis. (2024) · cites this paper as [113]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
Self-citationA Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131
Self-citationLindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
Parés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756
Self-citationA Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
Poupon, R., Lindor, K., Cauch-Dudek, K., Dickson, E., Poupon, R., & Heathcote, E. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70183-5 · Cited by 648
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646
Self-citationA Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714519 · Cited by 642
Self-citationLammers, W. J., van Buuren, H. R., Hirschfield, G. M., Janssen, H. L. A., Invernizzi, P., Mason, A. L., Ponsioen, C. Y., Floreani, A., Corpechot, C., Mayo, M. J., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.029 · Cited by 498
Self-citationHirschfield, G. M., Dyson, J. K., Alexander, G. J. M., Chapman, M. H., Collier, J., Hübscher, S., Patanwala, I., Pereira, S. P., Thain, C., Thorburn, D., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315259 · Cited by 362
Self-citation
Cited by
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis
Kowdley, K. V., Bowlus, C. L., Levy, C., Akarca, U. S., Alvares-da-Silva, M. R., Andreone, P., Arrese, M., Corpechot, C., Francque, S. M., Heneghan, M. A., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2306185 · Cited by 314
Self-citationTanaka, A., Ma, X., Takahashi, A., & Vierling, J. M. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01303-5 · Cited by 177
Ferraioli, G., Barr, R. G., Berzigotti, A., Sporea, I., Wong, V. W., Reiberger, T., Karlas, T., Thiele, M. S., Cardoso, A. C., Ayonrinde, O. T., et al. (2024) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2024.03.013 · Cited by 187
Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis
Lam, L., Soret, P., Lemoinne, S., Hansen, B. E., Hirschfield, G. M., Gulamhusein, A. F., Montaño‐Loza, A. J., Lytvyak, E., Parés, A. R., Olivas, I., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.06.035 · Cited by 47
Self-citationWong, Y. J., Chen, V. L., Abdulhamid, A., Tosetti, G., Navadurong, H., Kaewdech, A., Cristiu, J., Song, M. W., Devan, P., Tiong, K. L. A., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000891 · Cited by 47
Metadata
- Authors
- Corpechot, C., Lemoinne, S., Soret, P.-A., Hansen, B., Hirschfield, G., Gulamhusein, A., Montano-Loza, A. J., Lytvyak, E., Pares, A., Olivas, I., Eaton, J. E., Osman, K. T., Schramm, C., Sebode, M., Lohse, A. W., Dalekos, G., Gatselis, N., Nevens, F., Cazzagon, N., Zago, A., Russo, F. P., Floreani, A., Abbas, N., Trivedi, P., Thorburn, D., Saffioti, F., Barkai, L., Roccarina, D., Calvaruso, V., Fichera, A., Delamarre, A., Sobenko, N., Villamil, A. M., Medina-Morales, E., Bonder, A., Patwardhan, V., Rigamonti, C., Carbone, M., Invernizzi, P., Cristoferi, L., van der Meer, A., de Veer, R., Zigmond, E., Yehezkel, E., Kremer, A. E., Deibel, A., Bruns, T., Große, K., Wetten, A., Dyson, J. K., Jones, D., Dumortier, J., Pageaux, G.-P., de Lédinghen, V., Chazouillères, O., Carrat, F., & Groups, T. G. &. E. R.-L. P. S.
- Affiliations
- Inserm (FR)
- University Health Network (CA)
- Division of Gastroenterology and Liver Unit, University of Alberta, Edmonton, Alberta, Canada
- University of Alberta (CA)
- Liver Unit, Hospital Clínic, University of Barcelona, The August Pi i Sunyer Biomedical Research Institute, Biomedical Research Networking Center in Hepatic and Digestive Diseases, European Reference Network on Hepatological Diseases (ERN Rare-Liver), Barcelona, Spain
- Universitat de Barcelona (ES)
- Mayo Clinic (US)
- University Medical Center Hamburg-Eppendorf (DE)
- University Hospital of Larissa (GR)
- KU Leuven (BE)
- University of Padua (IT)
- National Health Service (GB)
- National Institute for Health and Care Research (GB)
- The Royal Free Hospital (GB)
- University College London Institute for Liver and Digestive Health, Royal Free Hospital, London, UK
- Section of Gastroenterology and Hepatology, PROMISE, University of Palermo, Palermo, Italy
- University of Palermo (IT)
- Department of Hepatology, University Hospitals of Bordeaux, Pessac, France
- Hospital Italiano de Buenos Aires (AR)
- Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, Massachusetts
- Beth Israel Deaconess Medical Center (US)
- Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
- University of Milano-Bicocca (IT)
- Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands
- Tel Aviv Sourasky Medical Center (IL)
- University Hospital Zurich (CH)
- Universitätsklinikum Aachen (DE)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Hospices Civils de Lyon (FR)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Corresponding author
- Corpechot, Christophe
- ORCID
- Corpechot, Christophe
- Lemoinne, Sara
- Soret, Pierre-Antoine
- Hansen, Bettina
- Hirschfield, Gideon
- Gulamhusein, Aliya
- Lytvyak, Ellina
- Olivas, Ignasi
- Eaton, John E.
- Osman, Karim T.
- Schramm, Christoph
- Sebode, Marcial
- Lohse, Ansgar W.
- Dalekos, George
- Gatselis, Nikolaos
- Nevens, Frederik
- Cazzagon, Nora
- Zago, Alessandra
- Russo, Francesco Paolo
- Floreani, Annarosa
- Abbas, Nadir
- Trivedi, Palak
- Thorburn, Douglas
- Saffioti, Francesca
- Roccarina, Davide
- Sobenko, Natalia
- Villamil, Alejandra Maria
- Bonder, Alan
- Patwardhan, Vilas
- Rigamonti, Cristina
- Carbone, Marco
- Invernizzi, Pietro
- Cristoferi, Laura
- Zigmond, Ehud
- Yehezkel, Eyal
- Kremer, Andreas E.
- Deibel, Ansgar
- Bruns, Tony
- Große, Karsten
- Wetten, Aaron
- Dyson, Jessica Katharine
- Jones, David
- Dumortier, Jérôme
- Pageaux, Georges-Philippe
- Chazouillères, Olivier
- Carrat, Fabrice
- Venue
- Hepatology
- Published
- 2023-07-03
- Volume
- 79
- Issue
- 1
- Pages
- 39-48
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W4383058381
- Cited by
- 94
- References
- 22
- Citations by year
- 2026: 34 · 2025: 33 · 2024: 22 · 2023: 5
- FWCI
- 15.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Hepatology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by)
- Lirias (submittedVersion, other-oa)
- Padua Research Archive (University of Padova) (submittedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Falk Foundation
- Bristol-Myers Squibb
- Eli Lilly and Company
- GlaxoSmithKline
- Gilead Sciences
- CSL Behring
- Kowa Company
- National Institute for Health and Care Research (NIHR131359, NIHR200243, NF-SI-0513-10091)
- Eisai
- Swedish Orphan Biovitrum
- Ipsen
- AOP Orphan
- Grifols
- Dr. Falk Pharma
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- primary biliary cirrhosis, ursodeoxycholic acid, alkaline phosphatase, treatment response, complication-free survival, liver complications, liver transplantation, liver stiffness measurement, liver fibrosis, prognosis
- MeSH terms
- Alkaline Phosphatase, Cholagogues and Choleretics, Humans, Liver Cirrhosis, Biliary, Middle Aged, Retrospective Studies, Ursodeoxycholic Acid, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain? https://app.cochat.ai/papers/10.1097/hep.0000000000000529
- The paper
- Corpechot, C., Lemoinne, S., Soret, P.-A., Hansen, B., Hirschfield, G., Gulamhusein, A., Montano-Loza, A. J., Lytvyak, E., Pares, A., Olivas, I., Eaton, J. E., Osman, K. T., Schramm, C., Sebode, M., Lohse, A. W., Dalekos, G., Gatselis, N., Nevens, F., Cazzagon, N., . . . Groups, T. G. &. E. R.-L. P. S. (2024). Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain? Hepatology. https://doi.org/10.1097/hep.0000000000000529
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.